Differential Neuropathology, Genetics, and Transcriptomics in Two Kindred Cases with Alzheimer’s Disease and Lewy Body Dementia

• Published in: Biomedicines 2022-07, Vol.10 (7), p.1687
• Main Authors: Palmieri, Ilaria, Poloni, Tino Emanuele, Medici, Valentina, Zucca, Susanna, Davin, Annalisa, Pansarasa, Orietta, Ceroni, Mauro, Tronconi, Livio, Guaita, Antonio, Gagliardi, Stella, Cereda, Cristina
• Format: Article
• Language: English
• Subjects: Age; Alzheimer's disease; Antibodies; Basal ganglia; Brain; Cognitive ability; Dementia; Dementia disorders; Gene expression; Gene loci; Genetic analysis; Genetic diversity; Genetics; hippocampus; Lewy bodies; Lewy body dementia; Neurodegeneration; Neurodegenerative diseases; Neuropathology; Next-generation sequencing; Parietal lobe; Parkinson's disease; Pathology; Phenotypes; Proteins; Ribonucleic acid; RNA; Substantia nigra; Topography; Transcription; Transcriptomes; Transcriptomics
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10071687

Alzheimer’s disease (AD) and Lewy body dementia (LBD) are two different forms of dementia, but their pathology may involve the same cortical areas with overlapping cognitive manifestations. Nonetheless, the clinical phenotype is different due to the topography of the lesions driven by the different underlying molecular processes that arise apart from genetics, causing diverse neurodegeneration. Here, we define the commonalities and differences in the pathological processes of dementia in two kindred cases, a mother and a son, who developed classical AD and an aggressive form of AD/LBD, respectively, through a neuropathological, genetic (next-generation sequencing), and transcriptomic (RNA-seq) comparison of four different brain areas. A genetic analysis did not reveal any pathogenic variants in the principal AD/LBD-causative genes. RNA sequencing highlighted high transcriptional dysregulation within the substantia nigra in the AD/LBD case, while the AD case showed lower transcriptional dysregulation, with the parietal lobe being the most involved brain area. The hippocampus (the most degenerated area) and basal ganglia (lacking specific lesions) expressed the lowest level of dysregulation. Our data suggest that there is a link between transcriptional dysregulation and the amount of tissue damage accumulated across time, assessed through neuropathology. Moreover, we highlight that the molecular bases of AD and LBD follow very different pathways, which underlie their neuropathological signatures. Indeed, the transcriptome profiling through RNA sequencing may be an important tool in flanking the neuropathological analysis for a deeper understanding of AD and LBD pathogenesis.